Dr Karen Lewis joins Babraham Bioscience Technologies board
Dr Karen Lewis has joined the board of Babraham Bioscience Technologies (BBT) as a non-executive director.
BBT develops and manages the Babraham Research Campus and Dr Lewis has been nominated by Biotechnology and Biological Sciences Research Council (BBSRC), a public body that is a shareholder off BBT alongside the Babraham Institute.
Dr Lewis, who works as executive director, capability and innovation at BBSRC, has a PhD in microbiology and experience in commercial research and development within biotechnology companies.
She joins the seven-strong BBT board, which includes Professor Clive Page, the Babraham Institute nominee director, and independent non-executive directors Dr Jane Osbourn (MedImmune/AstraZeneca), Jo Parfrey, and Dr Andy Richards. BBT’s chief executive Derek Jones and CFO Becky Paxton are the executive directors on the Board.
“We are pleased to welcome Karen to the Board,” said BBT CEO Derek Jones. “She brings a wealth of knowledge and experience that will further strengthen and diversify our board, and we look forward to benefiting from her skills and perspective.”
Dr Lewis said: “I am delighted on my recent board appointment and look forward to the new opportunities to help shape the continued success of the Babraham Research Campus.”